Sugi Predict

Sugi Predict / Compounds / SCHEMBL993225

SCHEMBL993225

SCHEMBL993225

CC(C)(C)OC(=O)N1CCN(c2ccc(N)cc2Cl)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.55
▸ KDM4E B2RXH2 1/20 0.55
▸ RAD52 P43351 1/20 0.55
▸ NR1H2 P55055 1/20 0.54
▸ ALDH1A1 P00352 5/20 0.54
▸ GAA P10253 2/20 0.54
▸ POLB P06746 2/20 0.51
▸ SMARCA2 P51531 1/20 0.51
▸ SMARCA4 P51532 1/20 0.51
▸ PBRM1 Q86U86 1/20 0.51
▸ HTT P42858 2/20 0.50
▸ MEN1 O00255 2/20 0.49
▸ KMT2A Q03164 2/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ GPR119 Q8TDV5 1/20 0.48
▸ STS P08842 1/20 0.48
▸ LMNA P02545 1/20 0.48
▸ MAP4K4 O95819 1/20 0.46
▸ BACE1 P56817 2/20 0.46
▸ NPC1 O15118 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29508821 1.00 MAPT (0.55) MAPTKDM4ERAD52NR1H2ALDH1A1
SCHEMBL13419744 0.95 MEN1 (0.54) MAPTKDM4ERAD52NR1H2ALDH1A1
SCHEMBL23783335 0.89 GPR119 (0.59) MAPTNR1H2ALDH1A1HTTGPR119
SCHEMBL30207515 0.89 GPR119 (0.59) MAPTNR1H2ALDH1A1HTTGPR119
SCHEMBL5383294 0.86 NR1H2 (0.54) MAPTRAD52NR1H2ALDH1A1GAA
SCHEMBL29569426 0.86 NR1H2 (0.54) MAPTRAD52NR1H2ALDH1A1GAA
SCHEMBL30208133 0.86 MEN1 (0.58) MAPTALDH1A1POLBHTTMEN1
SCHEMBL2365793 0.86 MEN1 (0.58) MAPTALDH1A1POLBHTTMEN1
SCHEMBL660403 0.85 NR1H2 (0.53) MAPTNR1H2ALDH1A1SMARCA2SMARCA4
SCHEMBL8094544 0.85 NR1H2 (0.53) MAPTNR1H2ALDH1A1SMARCA2SMARCA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260109702-A1 NOVEL GSPT PROTEIN DEGRADER AND APPLICATION THEREOF GENOSCO INC (US) 2026-04-23 — — US disclosed
WO-2025137605-A1 COMPOUNDS FOR TARGETED DEGRADATION OF PROTO-ONCOGENE TYROSINE PROTEIN KINASE RECEPTOR C4 THERAPEUTICS, INC. (US) 2025-06-26 — — WO disclosed
US-20250101025-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2025-03-27 — — US disclosed
EP-4384521-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND Uppthera, Inc. (KR) 2024-06-19 — — EP disclosed
CN-117794936-A Novel PLK1 degradation inducing compounds 厄普特拉株式会社 2024-03-29 — — CN disclosed
CN-111566100-B Pyrimidine compound, preparation method and medical application thereof 恩瑞生物医药科技（上海）有限公司 2023-10-27 — — CN disclosed
WO-2023017446-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-02-16 — — WO disclosed
WO-2023018237-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-02-16 — — WO disclosed
WO-2023274390-A1 BRUTON'S TYROSINE KINASE AND MUTANT DEGRADER, COMPOSITION AND APPLICATION THEREOF 杭州和正医药有限公司 2023-01-05 — — WO disclosed
WO-2022192162-A1 NOVEL HETEROAROMATIC COMPOUNDS EXHIBITING ANTIFUNGAL ACTIVITY AND THEIR METHOD OF USE FOX CHASE CHEMICAL DIVERSITY CENTER, INC. (US) 2022-09-15 — — WO disclosed
US-7667039-B2 1,3-dihydro-imidazo [4,5-C] quinolin-2-ones as lipid kinase inhibitors NOVARTIS AG (CH) 2010-02-23 — — US disclosed
US-20080194579-A1 1,3-Dihydro-Imidazo [4,5-C] Quinolin-2-Ones as Lipid Kinase Inhibitors NOVARTIS AG (CH) 2008-08-14 — — US disclosed
EP-1888578-A2 IMIDAZOQUINOLINES AS LIPID KINASE INHIBITORS Novartis AG (CH) 2008-02-20 — — EP disclosed
US-20070249620-A1 Urea Derivative SANKYO COMPANY, LIMITED (JP) 2007-10-25 — — US disclosed
EP-1764360-A1 UREA DERIVATIVE Sankyo Company, Limited (JP) 2007-03-21 — — EP disclosed
WO-2006122806-A2 1,3-DIHYDRO-IMIDAZO [4,5-C] QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2006-11-23 — — WO disclosed
US-6069143-A Fibrinogen receptor antagonists SMITHKLINE BEECHAM CORPORATION (US) 2000-05-30 — — US disclosed
EP-0885213-A4 FIBRINOGEN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 1999-04-28 — — EP disclosed
EP-0885213-A1 FIBRINOGEN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1998-12-23 — — EP disclosed
WO-1997025323-A1 FIBRINOGEN RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1997-07-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250101025-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND PLK1, BUB1B, BUB1 MAPT 2055/4885KDM4E 1918/4885RAD52 1638/4885
US-20260109702-A1 NOVEL GSPT PROTEIN DEGRADER AND APPLICATION THEREOF CRBN, PSMB3, PSMB1 MAPT 3675/4885KDM4E 2393/4885RAD52 3174/4885
US-20080194579-A1 1,3-Dihydro-Imidazo [4,5-C] Quinolin-2-Ones as Lipid Kinase Inhibitors PDPK1, PI4KA, PIP4K2A MAPT 3946/4885KDM4E 2491/4885RAD52 4720/4885
US-20070249620-A1 Urea Derivative UGP2, SLC14A1, DGAT1 MAPT 758/4885KDM4E 2284/4885RAD52 3736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.